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Abstract
Background—Operative management of pancreatic ductal adenocarcinoma (PDAC) is 
complicated by several key decisions during the procedure. Identification of metastatic disease at 
the outset and, when none is found, complete (R0) resection of primary tumor are key to 
optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on 
photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. 
The first-in-human use of multimodality molecular imaging for intraoperative detection of 
pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that 
binds to epidermal growth factor receptor.
Methods—A dose-escalation study was performed to assess safety and feasibility of targeting 
and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients 
undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of 
unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-
instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence 
and photoacoustic imaging ex vivo.
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Results—Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled 
in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean 
fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 
± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 
67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding 
tissue.
Conclusions—The safety and feasibilty of intraoperative, tumor-specific detection of PDAC 
using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and 
metastases was demonstrated.
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, with an 
expected median survival of 25 months for patients undergoing surgery with adjuvant 
chemotherapy.1,2 After diagnosis of PDAC, patient selection for surgical resection is 
challenging at multiple stages during the procedure: detection of occult distant metastases, 
assessment of the extent of the primary tumor, peritumoral lymph nodes (LN), and the 
resection margins. Surgeons address two critical decisions during the procedure that will 
determine the long-term survival of pancreatic cancer: the absence of metastatic and regional 
disease and cancer-free margins.3–5 However, margin-positive resections are a frequent 
phenomenon (which occurs up to 70% of cases),6 as is the emergence of distant metastases 
soon after surgery.7 Failure to identify small tumor extensions during surgery is not 
surprising, due to the growth pattern of the tumor and the inability of the surgeon to 
differentiate between tumor and (peritumoral) inflammation.
The use of tumor-targeted imaging probes for photoacoustic and optical imaging modalities 
has the potential to provide real-time information to the surgeon to aid decision making. 
Photoacoustic imaging can provide intraoperative or transcutaneous images with functional 
information at clinically relevant depths (up to 5 cm) with submillimeter spatial resolution.8 
Fluorescent optical imaging, on the other hand, is superior for imaging of superficial lesions 
with a very high resolution.9
Despite significant investment in systemic therapy for small incremental gains in survival, 
there has been minimal investment in improving surgical outcomes. Although the value of 
intraoperative guidance in pancreatic cancer resection would seem obvious, previous studies 
have not demonstrated benefit when using the nonspecific imaging agent indocyanine green 
(ICG).10 Rosenthal et al. showed the successful use of cetuximab-IRDye800 to image sub-
clinical fragments of squamous cell carcinoma arising in the head and neck cancer patients.
11
 EGFR also is highly expressed in PDAC and is a good target for fluorescence imaging, 
due to its transmembrane position.12–15 This study is the first example of tumor-specific 
multimodality molecular imaging for the accurate detection of primary PDAC, tumor-
bearing LN, and distant metastases. The workflow of infusion, surgery, and imaging is 
shown in Fig. 1.
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MATERIALS AND METHODS
Experimental Design
This study is a single-arm, open-label, dose-escalation study; the main objectives were to 
determine the safety and feasibility of tumor-specific multimodal molecular imaging for 
intraoperative detection of PDAC. Patients with suspected or biopsy-proven PDAC 
scheduled to undergo surgical resection at Stanford University Hospital were identified. A 
pretreatment dose of 100 mg of unlabeled cetuximab was administered before the study drug 
to differentiate between a cetuximab reaction and a cetuximab-IRDye800 reaction and to 
saturate the EGFR receptors in normal tissues with high expression (antigen sinks).16 Two to 
five days after cetuximab-IRDye800 infusion, patients underwent surgery.
Investigational Agent: Cetuximab-IRDye800
The cetuximab-IRDye800 was produced under cGMP conditions at the University of 
Alabama (UAB) Vector Production Facility as previously described, before shipment to 
Stanford University Hospital Pharmacy (see also Supplementary Methods).17
Imaging
Intraoperative Near-Infrared (NIR) Imaging—Imaging during surgery was performed 
using the laparoscopic optical imaging system PINPOINT 9000 modified for IRDye800 
fluorescent dye imaging (Novadaq, Burnaby, Canada), and the wide-field SurgVision 
Explorer (SurgVision BV, ‘t Harde, The Netherlands). During surgery, imaging was 
performed during inspection of the abdomen, before resection for the primary tumor, and 
after resection for the wound bed. This procedure is described in detail in the Supplementary 
Materials. Subsequently, all excised tissues were imaged ex vivo at a separate table in the 
OR directly after removal. Next, the surgical specimen was processed by the pathologist 
according to standard clinical practice to determine tumor status.
Ex vivo Close-field NIR Imaging—The Pearl Impulse imaging platform (LI–COR 
Biosciences, Lincoln, NE) was used to image fresh tissues obtained in the operating room 
before paraffin embedding. The procedure is described in the supplementary methods.
Ex Vivo Photoacoustic Imaging—After excision of the specimen, ex vivo 
photoacoustic imaging was performed on the primary specimen and breadloaf sections of 
the tumor using a Stanford-build clinical hand-held photoacoustic imaging (PAI) and 
ultrasound transducer as previously described.18 For detailed description of the imaging 
analysis for both fluorescent and photoacoustic imaging, see Supplementary Methods.
Ethics Approval
This study is performed in accordance with the tenets established by the Helsinki 
Declaration of 1975, ICH-GCP guidelines, and the laws and regulations of the United States. 
The Stanford University Institutional Review Board and the FDA approved the study 
protocol. All patients provided written, informed consent before the start of any study-
related procedures. The study was registered in the Clinical Trials Database of the U.S. 
National Institutes of Health, under number NCT02736578.
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Pathologic Assessment
All resected lesions were examined for tumor status by a gastrointestinal pathologist with 
expertise in pancreatobiliary disease. A positive tumor that was fluorescent was considered a 
true positive, a negative lesion that was fluorescent was considered a false positive, and a 
positive tumor that was nonfluorescent was considered a false negative. Fluorescence 
positivity was determined based on the MFI of the raw data.
Histologic Correlation—Formalin-fixed, paraffin-embedded tumor tissues were 
sectioned at 4-μm thickness and fluorescence imaging was performed using the Odyssey 
NIR scanner (Li-COR Biosciences). All histologic sections were stained with standard 
hematoxylin–eosin (H&E). To confirm the presence of EGFR, additional sections underwent 
immunohistochemical (IHC) analysis for EGFR expression utilizing anti-human EGFR. In 
addition, Ki-67 proliferation index was determined by IHC. See Supplementary Methods for 
further details. Appropriate positive and negative controls were included and evaluated with 
the specimens tested.
Fluorescence Microscopy—FFPE slides were prepared for fluorescence microscopy 
using the methods described in Supplementary Materials.
Adverse Events
Adverse events were classified according to the National Cancer Institute Common 
Terminology Criteria (Version 4.0), see Supplementary Methods.
Statistical Analysis
SPSS statistical software package (version 23.0, IBM Corp.) was used for statistical 
analyses. Differences in fluorescent signal per tissue type (tumor, pancreatitis, normal 
pancreatic tissue) were tested separately and between different dose groups, with one-way 
ANOVA with posthoc Bonferroni correction.
RESULTS
Patient and Safety Data
Between July 2016 and April 2017, ten patients were screened for trial eligibility. Eight 
patients with suspected PDAC received a loading dose Cetuximab, and seven were enrolled. 
One patient was not enrolled, because he had an infusion reaction on the loading dose 
Cetuximab. The other seven patients received cetuximab-IRDye800. Patient and tumor 
characteristics are summarized in Table 1; 5 received 50 mg of cetuximab-IRDye800 (cohort 
1) and 2 received 100 mg of cetuximab-IRDye800. There was one CTCAE grade-2 adverse 
event in cohort 1: fever, possibly related to cetuximab or cetuximab-IRDye800. No other 
possibly related adverse events occurred (Table 1). Two patients had neuroendocrine tumors 
at pathologic assessment, and one patient did not undergo resection due to liver metastases. 
Consistent with the literature regarding cetuximab administration for therapeutic purposes, a 
small increase of QTc interval was seen after infusion of the loading dose cetuximab with no 
further increase after cetuximab-IRDye800.19,20 QTc interval gradually decreased to 
baseline and none of the patients had persistent increased QTc after the observation period.
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Intraoperative NIR Fluorescent Imaging
Laparoscopic NIR-imaging was performed at the diagnostic laparoscopy before resection. 
All surgeries, except one, were converted to an open procedure, and widefield NIR imaging 
was performed during the subsequent procedure. The primary pancreatic tumor and/or LN 
could be clearly identified in every patient: bright-field (Figs. 2a, e), overlay (Figs. 2b, f), 
grayscale (Figs. 2c, g), and heat-map (Fig. 2d, h). Fluorescence imaging provided a clear 
contrast between tumor and surrounding tissues for both the primary tumor and LN 
dissection. The primary tumor could be identified in four of the six patients during surgical 
resection, with mean TBR of 2.3 ± 0.72. In the other two patients, the tumor was situated 
below the peripancreatic fat (> 5-mm depth) and therefore was intraoperatively not visible 
using NIR fluorescence. During surgery, tumor-bearing LN could be identified with mean 
TBR of 6.3 ± 0.82. Back table imaging of the primary tumor in all patients demonstrated a 
mean TBR of 3.4 ± 0.4.
Correlation of Fluorescence with Histological Disease
Correlation between fluorescent signal and histologic evidence of disease was established 
using close-field fluorescence imaging (Fig. 3). The average fluorescent signal was 
significantly different in normal pancreatic tissue (MFI 0.02 ± 0.01), pancreatitis (MFI 0.04 
± 0.02), and tumor (MFI 0.09 ± 0.06) (p < 0.001) (Fig. 3K). This allows tumor detection 
with a sensitivity of 96.1% (CI 92.19–98.43%) and specificity of 67.0% (CI 59.69–73.81%). 
There was no significant difference in MFI between normal pancreatic tissue (MFI 0.02 
± 0.01; 0.03 ± 0.02), pancreatitis (MFI 0.03 ± 0.02; 0.06 ± 0.03), and PDAC (MFI 0.09 
± 0.06; 0.1 ± 0.05) between the low and high dose cohort, respectively. Tumor-bearing LN 
(n = 29) could be detected with significantly higher MFI (0.06 ± 0.01) compared with 
tumor-negative (n = 78) LN (0.02 ± 0.002) (p < 0.001; Fig. 3l). Interestingly, liver 
metastases could be detected as well by negative contrast (Fig. S1).
Ex vivo Photoacoustic Imaging
Ex vivo photoacoustic imaging of primary tumor and LN was performed using a custom 
built photoacoustic imaging system to determine the potential utility of this strategy for 
eventual in vivo use.21 In this study, photoacoustic imaging could successfully be performed 
in all patients (n = 4). (The device was not available for two patients). There was a clear 
increase in photoacoustic imaging signal in the primary tumor compared with surrounding 
pancreatic tissue (Fig. S2) and in the tumor-bearing LN (Fig. 4), which was consistent with 
the optical fluorescence imaging results. The mean photoacoustic signal in the tumor 
(32,286 ± 1660 AU) was significantly higher compared to background (8651 ± 902 AU) (p < 
0.001), which indicates a mean 3.7-fold increase in signal in the tumor compared to 
surrounding tissue (Fig. 4g). A difference in signal-to-noise ratio (SNR) was observed 
between patients, as shown in Fig. 4h. This trend was comparable to the difference in 
fluorescence imaging results in the same patients (Fig. S2 and S3D).
Molecular Correlation
The correlation of fluorescence on microscopic level (Fig. S3, panel I) was performed to 
correlate the uptake of the antibody-dye bioconjugate in the tumor but not surrounding 
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stromal elements. To perform this analysis, a grid was overlaid on the fluorescently scanned 
slides to determine the MFI per specific area and then mapped to the histological grid as 
shown in (Fig. S3, panel II). The tumor could be identified with a sensitivity of 95% (CI 
92.8–96.8%), specificity of 61% (CI 58.8–63.2%), AUC of 0.84 (CI 0.82–0.85), and a 
positive- and negative-predicting values of 37.8 and 98.0%, respectively. MFI also was 
correlated with EGFR expression (Fig. S3, panel III). In Fig. S3D, the MFI per patient per 
tissue type is shown. A clear difference can be detected in MFI per patient. This is likely due 
to the heterogeneity of EGFR expression between tumors. Patient 4 had relatively strong 
EGFR expression, patients 5 and 6 had moderate EGFR expression, and patients 1–3 had 
low expression (Fig. S3E). Although low EGFR expression in the tumor is seen in those 
patients, a clear difference in the MFI between tumor and surrounding pancreatic tissue 
could be detected (Fig. S3D).
To localize cetuximab-IRDye800 within the tumor cells, we used fluorescence microscopy. 
Figure S4 shows representative images of the 800-nm fluorescent signal at the tumor ducts 
but not adjacent stromal tissues. Importantly, fluorescent signal (serving as a surrogate for 
the antibody-dye bioconjugate) is identified within the tumor ducts, indicating the successful 
antibody penetration into the tumor.
DISCUSSION
We demonstrated for the first time the safety and efficacy of tumor-specific multimodality 
molecular imaging in the detection of pancreatic cancer using NIR fluorescently-labeled 
antibody. Current metabolic and anatomic imaging modalities often fail to detect small 
tumor lesions or tumor-bearing LN, and as a result, intraoperative identification of the 
disease is critical to help guide decision making and precision surgery.
We found a significant difference in fluorescent signal between tumor-bearing and negative 
LN at the lower dose (50 mg); however, at the higher dose (100 mg), we observed an 
increased number of false-positive fluorescent LN. We hypothesize that this is caused by 
lymphatic drainage of excess antibody to the primary nodal basin, which is similar to 
findings with cetuximab-IRDye800 in head and neck cancer.22 We have shown that this 
technique can guide tumor-bearing LN detection and removal when used at the optimal 
dose, which can be beneficial in patients with tumor-bearing LN in the first-echelon (N1).23 
Therefore, the optimal dose Cetuximab-IRDye800 established in this study is 50 mg, with a 
loading dose of 100 mg cetuximab. Due to variety of the infusion window in this study 
between cetuximab-IRDye800 infusion and surgery, no conclusion can be drawn if a specific 
timing is optimal. We can conclude that all intervals in the infusion window, 2–5 days before 
surgery, provide clear tumor-to-background ratios and therefore are sufficient for this 
purpose.
We have previously shown that EGFR has high levels of expression in the primary tumor 
and tumor-bearing LN, a finding that is confirmed by the results of our current study using 
EGFR as a target.15 A difference in EGFR expression between neuroendocrine tumors and 
PDAC was seen (Fig. S3D) with lower expression in neuroendocrine tumors, resulting in 
subsequent lower absolute fluorescence signal. Nevertheless, in both patients with 
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neuroendocrine tumors, the background signal in normal pancreatic tissue was three times 
lower to provide sufficient TBRs for detection. High expression of EGFR in the stomach and 
duodenum resulted in high levels of background fluorescence in these organs. We 
hypothesize that this is located in normal luminal epithelium, because fluorescence 
correlated with EGFR and Ki-67 expression at this position (Fig. S5). Background 
fluorescence from these organs, however, did not interfere with detection of the primary 
tumor or LN during surgery, partly because the stomach and duodenum can be retracted 
away from the pancreatic tumor.
Furthermore, the potential of this technique to differentiate between PDAC and pancreatitis 
is crucial, because this is a difficult distinction to make both before surgery and 
intraoperatively, leading to approximately 7% of pancreatic resections being performed for 
benign conditions.24 Fluorescence imaging also may add value for margin assessment: in 
one patient, a positive pancreatic neck margin was evident during back-table imaging with 
clear fluorescence being visualized in the pancreatic neck, also confirmed by ex vivo 
imaging at pathology (Fig. S6). This preliminary observation supports the notion that this 
technology may be useful for real-time identification of close or positive margins during 
resection, but future prospective studies are needed in this direction.
The observed negative contrast of tumor in the liver may be related to the intensity of 
fluorescence in the normal surrounding liver, because it is known that the amount of 
fluorescent dye coupled to EGFR targeting antibodies will influence the biodistribution of 
the conjugate. Our conjugate has a dye/protein ratio of 1.8, which indicates that some 
molecules will have two or more eq of dye coupled to the antibody.17 Those are known to 
have the tendency for increased liver uptake.25 Another explanation can be the difference in 
EGFR expression in the metastases, which was clearly lower than surrounding hepatocytes.
It is worth noting that cetuximab-IRDye800 clearly penetrates the tumor and reaches the 
tumor cells. Limited success rates of phase II-III clinical trials on PDAC are commonly 
attributed to the presence of dense desmoplastic stroma, consisting of cellular and acellular 
components.26–31 This is thought to reduce severely the delivery of systemically 
administered therapies to the tumor and contribute the unresponsiveness of PDAC to 
systemic chemotherapy. We show at least to some extent that the EGFR monoclonal 
antibody can indeed reach the tumor successfully.
The main limitation of the study was the small sample size; however, it was sufficient for a 
proof-of-principle study investigating the safety and feasibility of multimodal molecular 
imaging in pancreatic cancer patients and to identify significant results in the detection of 
tumor, and tumor-bearing LN. A second limitation is based on the limited depth penetration 
of NIR fluorescent imaging. For pancreatic cancer, an imaging depth of 1 cm, achieved by 
fluorescence when used as single modality, is not enough to capture successfully the spatial 
features of the tumor. The combination with photoacoustic imaging can overcome the 
limited depth penetration.
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CONCLUSIONS
This is the first-in-human study to evaluate the use of multimodality molecular imaging in 
patients undergoing surgical resection for pancreatic cancer. Our findings emphasize that the 
technique is safe and feasible for this pilot patient population. This type of tumor-specific 
imaging could be leveraged for a range of diagnostic techniques, including detection of 
metastatic disease, identification of the primary tumor and tumor-bearing LN, assessment of 
resection margins, and identification of residual disease at the tumor bed after resection. 
Whether this additional information can change surgical management over commonly used, 
conventional methods remains to be determined in future, prospective trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIG. 1. 
Workflow of clinical trial with imaging examples. 1. Infusion. Infusion of a loading dose 
cetuximab (100 mg), and cetuximab-IRDye800 (50 or 100 mg) 2-5 days before surgical 
resection. 2. Operating room. Intra-operative fluorescence imaging. 3. Ex vivo imaging—
pathology. Ex vivo fluorescenceand photoacoustic imaging of surgical specimens. 4. 
Histology correlation. Histologic correlation between histologically proven tumor or 
normal tissue with H&E and fluorescent signal
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FIG. 2. 
Intraoperative fluorescent imaging. Lesions could be clearly identified as shown in this 
figure; bright-field (A and E), overlay (B and F), grayscale (C and G), and heat-map (D and 
H) fluorescence imaging provided clear contrast between tumor and surrounding tissues 
during a Whipple procedure for both the primary tumor (A–D) and lymph nodes (E–H). PF 
peripancreatic fat
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FIG. 3. 
Correlation between intraoperative fluorescence and tumor-status. Identification of primary 
tumor (A) and tumor-bearing lymph node using fluorescence (B), with corresponding ex 
vivo fluorescence (C and D). Fluorescence of the primary tumor (E) is shown, and bisected 
lymph node on mesoscopic scale (F), with enhancements corresponding to the tumor on 
H&E, outlined in red (G + H)), and increased EGFR expression, also outlined (I + J). A 
graphic representation is shown of the mean fluorescence intensity (MFI) in normal 
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pancreatic tissue, pancreatitis and tumor (K), and tumor-bearing and tumor-negative nodes 
(L). Scale bar represents 1 cm, unless indicated differently. ***p < 0.001
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FIG. 4. 
Photoacoustic and fluorescence imaging of tumor-bearing lymph node. Conventional 
ultrasound image of lymph node, surrounded by white dotted line and corresponding 
photoacoustic image (A). Mean photoacoustic signal in normal pancreatic tissue and tumor, 
and the signal-to-noise ratio (SNR) in photoacoustic signal per patient (B). Corresponding 
bright field (C), fluorescence overlay (D), heat-map fluorescent (E) images, and H&E 
section with outlined tumor (F) of tumor-bearing lymph node. ***p < 0.001. Scale bar 
represents 1 cm, unless indicated differently
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